Difference between revisions of "Epithelioid sarcoma"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |s...") |
m |
||
| Line 6: | Line 6: | ||
|- | |- | ||
|} | |} | ||
| + | Note: these are regimens tested in subtype-specific populations, please see the '''[[Soft_tissue_sarcoma|main soft tissue sarcoma page]]''' for other regimens. | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Revision as of 19:22, 3 February 2020
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN  ejdavis25
|
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tazemetostat monotherapy
| back to top |
Regimen
| FDA-recommended dose |
| Study | Evidence |
|---|---|
| See note | Phase II (RT) |
Note: this study has not yet been published, to our knowledge.
Chemotherapy
- Tazemetostat (Tazverik) 800 mg PO twice per day
Continued indefinitely
References
- EZH-202: CT.gov